Molecular Features, Effective Sources, and Physiological Effects of Omega-3 Unsaturated Fatty Acids on Cardiovascular, Neurological, and Muscular Health, and Clinical Relevance for Several Conditions: A Narrative Review.
Level 5 - mechanism / opinion, no new human data
Narrative review synthesizing existing literature without systematic review or meta-analytic methodology.
PubMed 41189116 · doi:10.1093/nutrit/nuaf201
What was done
This narrative review analyzed and compared the bioavailability, physiological effects, and clinical applications of plant-derived alpha-linolenic acid (ALA) versus marine- and microalgae-derived eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) across cardiovascular, neurological, and muscular health outcomes.
What was found
EPA and DHA demonstrated superior bioavailability and clinical efficacy compared to ALA, which has limited endogenous conversion requiring high doses (>20 g/d) for comparable effects. EPA and DHA at doses of 2-4 g/d reduced triglycerides by an average of 15% to 30% and lowered inflammatory markers (interleukin-6 and tumor necrosis factor-α). Formulations with higher EPA:DHA ratios (2:1 or greater) at doses of 1-2 g/d of EPA were reported to be more effective for depressive symptoms.
Why it matters
The paper synthesizes evidence distinguishing direct EPA/DHA supplementation from ALA precursor intake, highlighting specific clinical dosing thresholds for hypertriglyceridemia and mood support, and noting microalgae as an effective alternative for plant-based diets.
Limits
As a narrative review, it lacks systematic search criteria, quality appraisal, and meta-analytic pooling. The abstract notes broad gaps in the underlying literature, including a lack of direct head-to-head trials comparing different omega-3 sources and an absence of standardized dosing and evaluation protocols.
Cited by
- supports Omega-3 fatty acids and coenzyme Q10 support cardiovascular health, brain health, and cellular energy.